BioCryst Pharmaceuticals Inc.
- BID
7.964
- ASK
8.086
- 2,511 Units1,469 Units
- 07/21, 12:52:31 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
11.40%
Market Cap
1.42 Bil.
P/E Ratio
6.46
Dividend Yield
0.00 %
Earnings per Share
1.07 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 7.964 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 12:51:29 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 7.964 | 7.924 |
| PREV. DAY'S PRICE | 7.98 | (07/20) |
| CHANGE DAY BEFORE | -0.02 | -0.20 % |
| 52 WEEK HIGH / LOW | 9.93 (03/24) | 5.202 (02/06) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -1.09 | -0.40 | 1.07 | -2.24 | 0.51 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | 6.46 | - | 15.85 |
PRICE - BOOK RATIO | - | - | - | - | - |
PRICE - SALES RATIO | 3.47 | 3.45 | 1.95 | - | - |
PRICE - CASH FLOW RATIO | - | - | 5.17 | - | - |
Master Data
| WKN | 896047 |
| ISIN | US09058V1035 |
| SYMBOL | BO1 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | BioCryst Pharmaceuticals |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 206.15 Mil. |
| MARKET CAPITALISATION | 1.42 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -11.17 % | 4.50 % | 0.92 % | 42.43 % | 11.40 % | 27.11 % | -37.99 % | 25.97 % |
| HIGH | 9.06 | 9.75 | 9.75 | 9.93 | 9.93 | 9.93 | 17.11 | 9.93 |
| LOW | 7.83 | 7.74 | 6.96 | 5.20 | 5.20 | 3.76 | 3.76 | 5.20 |
Dividende
pro Aktie
BioCryst Pharmaceuticals does not deliver dividend information
Company profile
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.